Markers of cartilage and synovium turnover in OA patients with and without joint swelling in ibuprofen and placebo groups
| Placebo | Ibuprofen | Overall | ||||
|---|---|---|---|---|---|---|
| Joint swelling | Yes (n = 36) | No (n = 9) | Yes (n = 91) | No (n = 65) | Yes (n = 127) | No (n = 74) |
| Means are geometric means. | ||||||
| Paired test v baseline: *p = 0.001; †p = 0.011. | ||||||
| Unpaired test v patients without joint swelling: ‡p = 0.011; §p = 0.038; ¶p = 0.015; **p = 0.025. | ||||||
| ††One way multiple analysis of covariance model with treatment, presence of joint swelling, and treatment × joint swelling as factors and log(baseline) as a covariate. | ||||||
| Cartilage marker: CTX-II (ng/mmol Cr) | ||||||
| Baseline, mean (SD in log scale) | 245 (0.58) | 164 (0.73) | 251§ (0.82) | 194 (0.67) | 249‡ (0.76) | 190 (0.67) |
| Week 4–6, mean (SD in log scale) | 295 (0.65) | 174 (0.87) | 253 (0.76) | 199 (0.63) | 265 (0.73) | 196 (0.66) |
| Intra-treatment ratio, mean (95% CI)§ | 1.22* (1.09 to 1.37) | 1.01 (0.80 to 1.27) | 1.03 (0.96 to 1.11) | 1.00 (0.92 to 1.09) | 1.06 (1.00 to 1.13) | 1.03 (0.95 to 1.12) |
| Inter-treatment ratio, mean (95% CI)†† | 0.84 (0.74 to 0.97) | |||||
| p value for treatment effect | 0.014 | |||||
| Synovium marker: Glc-Gal-PYD (nmol/mmol Cr) | ||||||
| Baseline, mean (SD in log scale) | 5.9 (0.35) | 4.9 (0.37) | 6.4** (0.42) | 5.5 (0.36) | 6.2¶ (0.41) | 5.4 (0.36) |
| Week 4–6, mean (SD in log scale) | 6.6 (0.31) | 5.2 (0.44) | 6.4 (0.45) | 5.9 (0.30) | 6.5 (0.42) | 5.8 (0.32) |
| Intra-treatment ratio, mean (95% CI) | 1.12† (1.03 to 1.22) | 1.01 (0.85 to 1.20) | 1.03 (0.98 to 1.09) | 1.06 (0.99 to 1.13) | 1.04 (0.99 to 1.09) | 1.08 (1.01 to 1.15) |
| Inter-treatment ratio, mean (95% CI)†† | 0.92 (0.83 to 1.02) | |||||
| p value for treatment effect | NS | |||||